SARS-CoV-2 Vaccination in the Context of Ongoing HIV Cure-Related Research Studies

J Acquir Immune Defic Syndr. 2021 Aug 1;87(4):e232-e233. doi: 10.1097/QAI.0000000000002690.

Michael J Peluso¹, Lynda Dee^{2

3

4

5}, Jeff Taylor^{3

5

6

7}, Danielle M Campbell^{4

5

8}, Adam Ehm^{4

9}, Moisés Agosto-Rosario^{4

10}, Shirley Shao¹, Meghann C Williams¹, Rebecca Hoh¹, Rachel L Rutishauser¹¹, Steven G Deeks^{1

12}, John A Sauceda¹³, Karine Dubé^{13

14}

¹ Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco (UCSF), San Francisco, CA.
² AIDS Action Baltimore, Baltimore, MD.
³ amfAR Institute for HIV Cure Research Community Advisory Board.
⁴ Delaney AIDS Research Enterprise (DARE) Community Advisory Board.
⁵ Martin Delaney Collaboratory Community Advisory Board.
⁶ HIV + Aging Research Project (HARP-PS), Palm Springs, CA.
⁷ University of California, San Diego (UCSD) AntiViral Research Center (AVRC) Community Advisory Board, San Diego, CA.
⁸ Charles R. Drew University of Medicine and Science, Los Angeles, CA.
⁹ Living Positive Victoria, Victoria, Australia.
¹⁰ National Minority AIDS Council, Washington, D.C.
¹¹ Division of Experimental Medicine, UCSF, San Francisco, CA.
¹² amfAR Institute for HIV Cure Research, San Francisco, CA and New York City, NY.
¹³ Center for AIDS Prevention Studies (CAPS), UCSF, San Francisco, CA.
¹⁴ University of North Carolina (UNC) Gillings School of Global Public Health, Chapel Hill, NC.

No abstract available

Publication types